niacinamide

Summary

Summary: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.

Top Publications

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  2. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  4. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
  5. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
  6. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
  7. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
  8. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
  9. ncbi Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
    Wei Tien Tai
    National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    J Hepatol 55:1041-8. 2011
  10. ncbi Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
    Scott Wilhelm
    Department of Cancer Research, Bayer Pharmaceuticals Corp, West Haven, Connecticut 06516, USA
    Nat Rev Drug Discov 5:835-44. 2006

Detail Information

Publications279 found, 100 shown here

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  2. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
    ....
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  4. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ....
  5. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
    ..In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed...
  6. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
    ....
  7. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  8. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
    ..There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy...
  9. ncbi Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
    Wei Tien Tai
    National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    J Hepatol 55:1041-8. 2011
    ..Here, we report that sorafenib inhibits HCC via a kinase-independent mechanism: SHP-1 dependent STAT3 inactivation...
  10. ncbi Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
    Scott Wilhelm
    Department of Cancer Research, Bayer Pharmaceuticals Corp, West Haven, Connecticut 06516, USA
    Nat Rev Drug Discov 5:835-44. 2006
    ....
  11. pmc Phase II trial of sorafenib in advanced thyroid cancer
    Vandana Gupta-Abramson
    Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 26:4714-9. 2008
    ....
  12. ncbi NAD+ metabolism in health and disease
    Peter Belenky
    Departments of Genetics and of Biochemistry and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    Trends Biochem Sci 32:12-9. 2007
    ....
  13. pmc Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
    ..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
  14. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  15. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ....
  16. ncbi Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Yong S Chang
    Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 59:561-74. 2007
    ..The effect of sorafenib on tumor growth and tumor histology was assessed in both ectopic and orthotopic mouse models of RCC...
  17. ncbi Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1
    S Huber
    Third Department of Medicine, Technical University, Munich, Germany
    Leukemia 25:838-47. 2011
    ..Conclusively, sorafenib is highly active in CLL and may compose a new therapeutic option for patients who relapse after immunochemotherapy...
  18. ncbi Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
    Marie José Blivet-Van Eggelpoël
    UPMC Univ Paris 06, UMR_S 938, F 75012 Paris, France
    J Hepatol 57:108-15. 2012
    ..However, primary and acquired resistance is observed in patients. We examined whether gefitinib, which inhibits both epidermal growth factor receptor (EGFR) and HER-3 phosphorylation, could improve HCC cell response to sorafenib...
  19. ncbi Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1
    Kevin J Bitterman
    Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:45099-107. 2002
    ..We discuss the possibility that nicotinamide is a physiologically relevant regulator of Sir2 enzymes...
  20. ncbi Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+
    Peter Belenky
    Departments of Genetics and Biochemistry and the Norris Cotton Cancer Center, Dartmouth Medical School, Rubin 733 HB7937, Lebanon, NH 03756, USA
    Cell 129:473-84. 2007
    ..Thus, like calorie restriction in the mouse, nicotinamide riboside elevates NAD(+) and increases Sir2 function...
  21. ncbi Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, No 7, Chung Shan S Rd, Taipei, Taiwan
    J Pharmacol Exp Ther 337:155-61. 2011
    ..In conclusion, activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in HCC, and the combination of sorafenib and MK-2206, an Akt inhibitor, overcomes the resistance at clinical achievable concentrations...
  22. pmc PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways
    Roberto Gedaly
    Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY 40536, USA
    Anticancer Res 30:4951-8. 2010
    ..This study reports how sorafenib (a multi-kinase inhibitor) and PI-103 (a dual PI3K/mTOR inhibitor) alone and in combination inhibit the proliferation of the HCC cell line, Huh7...
  23. ncbi Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme
    Jose L Avalos
    Howard Hughes Medical Institute, Department of Biophysics and Biophysical Chemistry, School of Medicine, Johns Hopkins University, 725 N Wolfe Street, Baltimore, Maryland 21205, USA
    Mol Cell 17:855-68. 2005
    ..The characteristics of the altered specificity enzyme establish that Sir2 enzymes contain a single site that participates in catalysis and nicotinamide regulation and provides additional insights into the Sir2 catalytic mechanism...
  24. ncbi Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    Clin Cancer Res 18:2290-300. 2012
    ..One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy...
  25. ncbi Motesanib diphosphate in progressive differentiated thyroid cancer
    Steven I Sherman
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77230 1402, USA
    N Engl J Med 359:31-42. 2008
    ..Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT...
  26. ncbi EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
    Zakaria Ezzoukhry
    Inserm U1088, Faculte de Medecine, Universite de Picardie Jules Verne, Amiens, France
    Int J Cancer 131:2961-9. 2012
    ..Our findings bear possible implications for the improvement of the efficacy of sorafenib in HCC, and might be useful for the identification of predictive biomarkers in this context...
  27. ncbi Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3
    Wei Tien Tai
    Department of Medical Research, National Taiwan University Hospital, Chung Shan S Rd, Taipei 100, Taiwan
    Mol Cancer Ther 11:452-63. 2012
    ..In conclusion, dovitinib induces significant apoptosis in HCC cells and sorafenib-resistant cells via SHP-1-mediated inhibition of STAT3...
  28. ncbi Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro
    Anders Ullen
    Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 17176 Stockholm, Sweden
    Int J Oncol 37:15-20. 2010
    ....
  29. ncbi Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
    Ying Hong Shi
    Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
    Autophagy 7:1159-72. 2011
    ..The combination of autophagy modulation and molecular targeted therapy is a promising therapeutic strategy in treatment of HCC...
  30. ncbi Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
    ..S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC)...
  31. ncbi Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
    Martin J Schlumberger
    Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 27:3794-801. 2009
    ....
  32. ncbi The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib
    Hayato Hikita
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Hepatology 52:1310-21. 2010
    ..Sorafenib, not alone but in combination with ABT-737, efficiently induced apoptosis in hepatoma cells. This combination also led to stronger suppression of xenograft tumors than sorafenib alone...
  33. ncbi Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA, USA
    J Clin Oncol 25:2369-76. 2007
    ..This phase I, dose-finding study evaluated the safety, pharmacokinetics, and pharmacodynamics of AMG 706 in patients with refractory advanced solid tumors...
  34. ncbi AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts
    Anthony Polverino
    Department of Oncology Research, Amgen, Inc, Thousand Oaks, CA 91320 1799, USA
    Cancer Res 66:8715-21. 2006
    ..In summary, AMG 706 is an orally bioavailable, well-tolerated multikinase inhibitor that is presently under clinical investigation for the treatment of human malignancies...
  35. ncbi Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  36. ncbi A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    K N Chi
    Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
    Ann Oncol 19:746-51. 2008
    ..The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer...
  37. ncbi Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
    Julien Edeline
    Department of Medical Oncology, Eugene Marquis Center, Rennes, France
    Cancer 118:147-56. 2012
    ..In the current study, mRECIST were evaluated and were compared with RECIST in patients who received Sor for advanced HCC...
  38. ncbi Molecular mechanisms of sorafenib action in liver cancer cells
    Melchiorre Cervello
    Institute of Biomedicine and Molecular Immunology Alberto Monroy, National Research Council CNR, Palermo, Italy
    Cell Cycle 11:2843-55. 2012
    ..Further functional analyses may determine whether these genes can serve as potential molecular targets for more effective anti-HCC strategies...
  39. pmc SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    Anthony B El-Khoueiry
    University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Suite 3459, Los Angeles, CA 90033, USA
    Invest New Drugs 30:1646-51. 2012
    ..Based on the role of the Ras-Raf-Mek-Erk pathway and the VEGF axis in biliary carcinomas, we conducted a phase II study of sorafenib in patients with advanced biliary cancers...
  40. pmc The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
    Xu Dong Qu
    Department of Radiology, Zhong Shan Hospital, Fudan University, Fenglin Road, Shanghai 200032, People s Republic of China
    BMC Cancer 12:263. 2012
    ..The present study sought to understand the efficacy of the combination of TACE and sorafenib in the treatment of advanced HCC...
  41. ncbi Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes
    Yue Lei Chen
    Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    Hepatology 53:1708-18. 2011
    ....
  42. pmc The vitamin nicotinamide: translating nutrition into clinical care
    Kenneth Maiese
    Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Molecules 14:3446-85. 2009
    ....
  43. ncbi Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area
    Ju Hyun Shim
    Center for Liver Cancer, National Cancer Center, 809 Madu 1 dong, Ilsan gu, Goyang, Goyang, Gyeonggi, 411 769, Republic of Korea
    J Cancer Res Clin Oncol 135:617-25. 2009
    ..This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection...
  44. ncbi Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
    B Blanchet
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, France
    J Pharm Biomed Anal 49:1109-14. 2009
    ..Finally, large interindividual variability and higher exposure in patients experiencing severe toxicity support the need for therapeutic drug monitoring to ensure an optimal exposure to sorafenib...
  45. ncbi Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
    W Zhao
    State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China
    Leukemia 22:1226-33. 2008
    ..These findings suggest that sorafenib may cause the loss of T-cell immune response by inducing apoptosis and targeting LCK. This could potentially lead to immunosuppression in patients with cancer...
  46. ncbi Sorafenib: a clinical and pharmacologic review
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:1943-55. 2010
    ..Sorafenib is approved for the treatment of advanced inoperable hepatocellular cancer and advanced renal cell cancer...
  47. ncbi Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    Christina K Augustine
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Mol Cancer Ther 9:2090-101. 2010
    ..These results show that sorafenib in combination with chemotherapy provides a novel approach to enhance chemotherapeutic efficacy in the regional treatment of in-transit melanoma...
  48. pmc Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
    Shengbing Huang
    Divisions of Oncology and Gastroenterology Hepatology, Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 9:742-50. 2010
    ..These data indicate that targeting STAT3 may enhance treatment efficacy against pancreatic cancer...
  49. ncbi Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
    Marc Mejias
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, CIBERehd, Barcelona, Spain
    Hepatology 49:1245-56. 2009
    ..Notably, beneficial effects of sorafenib against tissue damage and inflammation were also observed in splanchnic organs...
  50. ncbi Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
    Mohamed Rahmani
    Departments of Medicine, Biochemistry, and Pharmacology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia 23298
    J Biol Chem 280:35217-27. 2005
    ..Together, these findings demonstrate that BAY 43-9006 mediates cell death in human leukemia cells, at least in part, through down-regulation of Mcl-1 via inhibition of translation...
  51. ncbi NAD+ and vitamin B3: from metabolism to therapies
    Anthony A Sauve
    Department of Pharmacology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    J Pharmacol Exp Ther 324:883-93. 2008
    ....
  52. ncbi Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    ..The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval...
  53. pmc Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity
    Christopher M Gallo
    Department of Biochemistry and Molecular Genetics, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Mol Cell Biol 24:1301-12. 2004
    ..Pnc1, therefore, positively regulates Sir2-mediated silencing and longevity by preventing the accumulation of intracellular NAM during times of stress...
  54. ncbi Substrate-specific activation of sirtuins by resveratrol
    Matt Kaeberlein
    Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA
    J Biol Chem 280:17038-45. 2005
    ..In light of these findings, the mechanism accounting for putative longevity effects of resveratrol should be reexamined...
  55. pmc FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
    Keith W Pratz
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 115:1425-32. 2010
    ..These results have important implications for the potential therapeutic use of FLT3 inhibitors in that patients with newly diagnosed FLT3-mutant AML might be less likely to respond clinically to highly selective FLT3 inhibition...
  56. ncbi Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
    Eur J Med Chem 55:220-7. 2012
    ..In light of the pivotal role of phospho-STAT3 in promoting tumorigenesis and drug resistance, this novel SHP-1-activating agent may have therapeutic relevance in cancer therapy...
  57. ncbi Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
    Xin Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China
    Hepatobiliary Pancreat Dis Int 11:458-66. 2012
    ..This study aimed to assess the efficacy and safety of sorafenib in advanced HCC patients and explore its true value for specific subgroups...
  58. ncbi Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Invest New Drugs 30:382-6. 2012
    ..Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease...
  59. ncbi A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
    William J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Eur J Cancer 49:312-22. 2013
    ....
  60. ncbi Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
    Keith T Flaherty
    Massachusetts General Hospital, 55 Fruit St, Yawkey 9E, Boston, MA 02114, USA
    J Clin Oncol 31:373-9. 2013
    ..The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with metastatic melanoma...
  61. ncbi Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
    Pedram Kharaziha
    Department of Oncology Pathology, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Cancer Res 72:5348-62. 2012
    ..Altogether, our data support the use of sorafenib as a novel therapeutic modality against human multiple myeloma, and its efficacy may be potentiated in combination with ABT737...
  62. ncbi Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
    Ying Chun Shen
    National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    J Gastroenterol 45:794-807. 2010
    ..Patient selection according to the individual molecular signature of the tumor and correlative biomarker studies are encouraged while planning a clinical trial of novel MTT...
  63. ncbi New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
    Yan Wang
    Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang, Hebei, China
    J Hepatol 53:132-44. 2010
    ....
  64. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  65. ncbi Phase II study of sorafenib in patients with relapsed or refractory lymphoma
    Anna Guidetti
    Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Br J Haematol 158:108-19. 2012
    ..Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens...
  66. ncbi Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
    Laurence Albiges
    Medical Oncology Department, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    J Clin Oncol 30:482-7. 2012
    ..It remains a matter of debate whether therapy should be continued after CR...
  67. ncbi Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo
    Yu Cheng Kuo
    Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, No 155, Sec 2, Li Nong St, Bei tou, Taipei 112, Taiwan
    Biomed Pharmacother 66:12-20. 2012
    ..The mechanism of synergism is through the inhibition of radiation-induced NF-κB expression and its regulated downstream gene products...
  68. pmc The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
    R Cabrera
    Division of Gastroenterology, Hepatology and Nutrition, Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Aliment Pharmacol Ther 34:205-13. 2011
    ..Standard of practice involves using transarterial therapy for multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more advanced HCC, but the sorafenib and transarterial therapy combination may provide greater efficacy...
  69. ncbi Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors
    Luigi Fiume
    Department of Experimental Pathology, University of Bologna, Via San Giacomo, 14 40126 Bologna, Italy
    Pharmacol Res 63:328-34. 2011
    ....
  70. pmc Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
    C Dudgeon
    Department of Pharmacology and Chemical Biology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Oncogene 31:4848-58. 2012
    ..They provide a rationale for manipulating the apoptotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogenic kinase signaling...
  71. ncbi Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats
    Kohtaro Abe
    Department of Pharmacology, University of South Alabama, Mobile, Alabama, USA
    Am J Respir Cell Mol Biol 45:804-8. 2011
    ..Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca(2+) desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation...
  72. ncbi Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
    Giovan Giuseppe Di Costanzo
    Liver Unit, Cardarelli Hospital, Naples, Italy
    Dig Liver Dis 44:788-92. 2012
    ..Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma...
  73. ncbi The protective effect of niacinamide on ischemia-reperfusion-induced liver injury
    C F Chen
    Division of Gastroenterology, Department of Internal Medicine, Cheng Hsin General Hospital, Taipei, Taiwan
    J Biomed Sci 8:446-52. 2001
    ..In this study, we demonstrated that niacinamide, a PARS inhibitor, attenuated ischemia/reperfusion (I/R)-induced liver injury...
  74. ncbi ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways
    J F Arthur
    Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
    J Thromb Haemost 10:1133-41. 2012
    ....
  75. ncbi Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial
    Geert O Janssens
    Radboud University Nijmegen Medical Centre, The Netherlands
    J Clin Oncol 30:1777-83. 2012
    ..To report the results from a randomized trial comparing accelerated radiotherapy (AR) with accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in laryngeal cancer...
  76. pmc Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 115:4090-5. 2009
    ..A phase 2 trial of sorafenib was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen...
  77. ncbi Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
    Iacopo Petrini
    Department of Oncology, Transplant and New Advances in Medicine, BIOS, University of Pisa, 67 Via Roma, 56126, Pisa, Italy
    Cancer Chemother Pharmacol 69:773-80. 2012
    ..However, aHCC patients' outcome is still poor despite these results. In order to improve the efficacy of systemic treatment for aHCC, we evaluated the combination of sorafenib plus 5-fluorouacil infusion in a phase II trial...
  78. ncbi Anti-tumor activity of motesanib in a medullary thyroid cancer model
    A Coxon
    Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Endocrinol Invest 35:181-90. 2012
    ..Motesanib is an investigational, orally administered small molecule antagonist of VEGFR1, 2, and 3; platelet-derived growth factor receptor (PDGFR); Kit; and possibly Ret...
  79. pmc Structural basis of substrate recognition in human nicotinamide N-methyltransferase
    Yi Peng
    Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106, United States
    Biochemistry 50:7800-8. 2011
    ..MD simulations revealed long-range conformational effects which provide an explanation for the large increase in K(m)(AdoMet) for the D197A mutant, which interacts directly only with nicotinamide in the ternary complex crystal structure...
  80. ncbi Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma
    Mohit Kasibhatla
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Genitourin Cancer 5:291-4. 2007
    ..This combination is promising and requires further study...
  81. pmc The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells
    Rui Huang
    Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
    Asian J Androl 12:527-34. 2010
    ..In conclusion, sorafenib induces apoptosis through a caspase-dependent mechanism with down-regulated anti-apoptotic proteins in androgen-independent prostate cancer cells in vitro...
  82. pmc High-resolution crystal structures of Streptococcus pneumoniae nicotinamidase with trapped intermediates provide insights into the catalytic mechanism and inhibition by aldehydes
    Jarrod B French
    Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, USA
    Biochemistry 49:8803-12. 2010
    ..These data provide structural evidence of several proposed reaction intermediates and allow for a more complete understanding of the catalytic mechanism of this enzyme...
  83. pmc BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing
    Aditi Pandya Martin
    Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Mol Pharmacol 76:327-41. 2009
    ....
  84. ncbi Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Sammy Saab
    Departments of Medicine, The University of California at Los Angeles, Los Angeles, CA, USA
    Exp Clin Transplant 8:307-13. 2010
    ..Liver transplant can be a definitive treatment for hepatocellular carcinoma. However, recurrence limits long-term survival. Sorafenib is the first agent to improve survival for patients with advanced hepatocellular carcinoma...
  85. pmc Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  86. ncbi Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1
    Yasukazu Nakahata
    Department of Pharmacology, School of Medicine, University of California, Irvine, Irvine, CA 92697, USA
    Science 324:654-7. 2009
    ..Our findings in mouse embryo fibroblasts reveal an interlocked transcriptional-enzymatic feedback loop that governs the molecular interplay between cellular metabolism and circadian rhythms...
  87. ncbi The Caenorhabditis elegans nicotinamidase PNC-1 enhances survival
    Armando van der Horst
    Department of Physiological Chemistry, Centre for Biomedical Genetics, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
    Mech Ageing Dev 128:346-9. 2007
    ..These data show for the first time the involvement of PNC-1/Nam in the survival of a multicellular organism and may also contribute to our understanding of lifespan regulation in mammals...
  88. ncbi Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells
    Carl Magnus Bäckesjö
    Department for Clinical Science, Intervention and Technology CLINTEC, Division of Orthopedics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
    J Bone Miner Res 21:993-1002. 2006
    ..However, adipocytes are also formed. We showed that activation of the nuclear protein deacetylase Sirt1 reduces adipocyte formation and promotes osteoblast differentiation...
  89. ncbi Sorafenib and radiation: a promising combination in colorectal cancer
    Andrew W Suen
    Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
    Int J Radiat Oncol Biol Phys 78:213-20. 2010
    ..To examine the combination of radiation and the multikinase inhibitor sorafenib in human colorectal cancer cell lines and xenografts...
  90. ncbi Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    BJU Int 108:E250-7. 2011
    ..To conduct a retrospective, multicentre, cohort analysis to assess the sequential use of the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib...
  91. ncbi A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
    G R Blumenschein
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 22:2057-67. 2011
    ..This phase II study estimated the difference in objective response rate (ORR) among patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) receiving paclitaxel-carboplatin (CP) plus motesanib or bevacizumab...
  92. ncbi Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
    Da Liang Ou
    National Center of Excellence for Clinical Trial and Research, Department of Oncology, National Taiwan University Hospital, Graduate Institute of Toxicology, Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
    Cancer Res 70:9309-18. 2010
    ..Together, our findings suggest that GADD45β induction contributes to sorafenib-induced apoptosis in HCC cells, prompting further studies to validate its potential value in predicting sorafenib efficacy...
  93. ncbi Toxicity of sorafenib: clinical and molecular aspects
    Benoit Blanchet
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, GH Cochin Saint Vincent de Paul, 75014 Paris, France
    Expert Opin Drug Saf 9:275-87. 2010
    ..Despite its inherent selectivity, sorafenib can cause unusual adverse events whose the management represents a challenge for oncologists...
  94. pmc Molecular dynamics simulations suggest ligand's binding to nicotinamidase/pyrazinamidase
    Ji long Zhang
    State Key Laboratory of Theoretical and Computational Chemistry, Institute of Theoretical Chemistry, Jilin University, Changchun, People s Republic of China
    PLoS ONE 7:e39546. 2012
    ..These results could provide the more penetrating understanding of drug resistance of M. tuberculosis and be helpful for the development of new antituberculosis drugs...
  95. ncbi Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
    Erika Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    Clin Cancer Res 16:4990-5001. 2010
    ..Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab...
  96. pmc Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2
    Boris R A Blechacz
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:1861-70. 2009
    ..In this in vivo model, sorafenib also decreased tumor Tyr(705) STAT3 phosphorylation and increased tumor cell apoptosis...
  97. ncbi Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway
    Chang Liang Peng
    Musculoskeletal Tumor Center, Peking University Peoples Hospital, Beijing, China
    Cancer Biol Ther 8:1729-36. 2009
    ..In conclusion, our findings demonstrate that sorafenib is effective for growth inhibition of synovial sarcoma cell lines in vitro and suggest that sorafenib may be a new therapeutic option for patients with synovial sarcoma...
  98. ncbi Sorafenib: a review of its use in advanced hepatocellular carcinoma
    Gillian M Keating
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand
    Drugs 69:223-40. 2009
    ....
  99. pmc Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
    Stephen K Williamson
    University of Kansas Cancer Center, Hematology Oncology Division, Westwood, KS 66205, USA
    J Clin Oncol 28:3330-5. 2010
    ..The primary end point was response probability (ie, confirmed complete and partial response [PR])...
  100. ncbi Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans
    Pawel Bieganowski
    Departments of Genetics and Biochemistry and the Norris Cotton Cancer Center, Dartmouth Medical School, Rubin 733 HB7937, Lebanon, NH 03756, USA
    Cell 117:495-502. 2004
    ..Nicotinamide riboside was discovered as a nutrient in milk, suggesting that nicotinamide riboside is a useful compound for elevation of NAD+ levels in humans...
  101. ncbi Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Clin Cancer Res 16:5189-99. 2010
    ..However, many hepatocellular carcinoma (HCC) cells show resistance to TRAIL-induced apoptosis. Here, we report that sorafenib improves the antitumor effect of TRAIL-related agents in resistant HCC...

Research Grants64

  1. NAD Metabolism and Signaling
    Frances E Lund; Fiscal Year: 2011
    ....
  2. A Novel Approach to Phosphorus Lowering in Patients with Chronic Kidney Disease
    Joachim H Ix; Fiscal Year: 2013
    ..If effective and well tolerated, this study will rapidly alter the standard of care by introducing icotinamide for Pi lowering in CKD stage 3-4. ..
  3. Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and Aging
    Joseph A Baur; Fiscal Year: 2013
    ....
  4. The role of nicotinamide N-methyltransferase in glucose and lipid homeostasis
    Pavlos Pissios; Fiscal Year: 2013
    ..This proposal has direct relevance to the NIDDK mission and will establish NNMT as a potential new candidate gene for the treatment of the metabolic syndrome. ..
  5. Mammalian Sir2 Function in Pancreatic Beta Cells
    Shin Ichiro Imai; Fiscal Year: 2012
    ....
  6. Probing functions of NAM and NAD+ salvage in development and aging in C. elegans
    Wendy Hanna-Rose; Fiscal Year: 2013
    ..abstract_text> ..
  7. The Effects of Vitamin B3 on Traumatic Brain Injury
    MICHAEL HOANE; Fiscal Year: 2009
    ..It is hoped that the research included in this proposal will help offset this major public health crisis by helping to identify a potential therapy for TBI. ..
  8. ANTICARCINOGENESIS BY NICOTINAMIDE A PROTEASE INHIBITOR
    Walter Troll; Fiscal Year: 1992
    ..With these experiments, we hope to learn the mechanism for preventing cancer and to identify a nontoxic PI, nicotinamide, available for testing in humans...
  9. NAD Metabolism and Signaling Conference
    JOHN DENU; Fiscal Year: 2009
    ..Programmatic discussions will emphasize integration of current knowledge to develop a systems biology view of the NAD+ metabolome. ..
  10. Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCC
    Brian Rini; Fiscal Year: 2008
    ..This project will have broad implications for the immunoregulation of cancer and how expression and modulation of COX-2 expression influences the immune response to cancer. [unreadable] [unreadable] [unreadable]..
  11. Combination Strategies for Angiogenesis Inhibition
    Keith Flaherty; Fiscal Year: 2008
    ..He is a recognized leader in the field of investigational therapies, has a record of mentoring successful clinical researchers, and is committed to Dr. Flaherty's training. ..
  12. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  13. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  14. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2008
    ..We will also monitor treatment/management changes, and evaluate acceptability of computer assessments and the perceived benefits of the recommendations. ..
  15. Sir2 regulation and chemical modulation
    Anthony A Sauve; Fiscal Year: 2010
    ..abstract_text> ..
  16. Brca1 Deletion in Murine Cells and Mammary Tissue
    MARCIA BROSE; Fiscal Year: 2007
    ..abstract_text> ..
  17. RNA directed silencing of HIV and SIV receptors
    Michael Murray; Fiscal Year: 2004
    ..abstract_text> ..
  18. 9th Immunology of Diabetes Society Research Symposium
    Desmond Schatz; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Discovery of Novel Cytotoxic Agents for Advanced Melanoma
    Wei Li; Fiscal Year: 2008
    ..This is a high risk, innovative proposal to discover a non-surgical means for a more selective and curative pharmacologic therapy for advanced melanoma. [unreadable] [unreadable] [unreadable]..
  20. Nogo receptor and its ligands in axon regeneration
    Zhigang He; Fiscal Year: 2008
    ..These animal models will be used in this study to define the role of myelin inhibitors and other intrinsic and extrinsic factors in limiting the regeneration of different axonal tracts in vivo ..
  21. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2008
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  22. The Renin-Angiotensin System in Hepatitis and Hepatoma
    Mary Maluccio; Fiscal Year: 2008
    ..The preclinical model involves a human hepatitis derived hepatocellular carcinoma xenograft into an immunodeficient mouse. [unreadable] [unreadable] [unreadable]..
  23. Does SIRT1 regulate mammalian health and longevity?
    JOSEPH BAUR; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  24. MOLECULAR PATHOGENESIS OF HEPATOCELLULAR CARCINOMA
    Lewis Roberts; Fiscal Year: 2008
    ..Successful completion of these studies will provide insight into the molecular pathogenesis of HCC, and may lead to the development of novel chemotherapeutic strategies against HCC. ..
  25. 2009 Biology of Aging Gordon Research Conference
    David Sinclair; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  26. Type-1 Diabetes: Zn2+ Potentiated Beta-Cell Death By Sirtuin-Mediated NAD+ Loss
    CHRISTIAN THOMAS SHELINE; Fiscal Year: 2010
    ..We show that niacinamide, pyruvate, NAD+, and sirtinol prevent Zn2+toxicity in neurons and beta-cells by counteracting the Zn2+-induced ..
  27. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2010
    ....
  28. Dynamic and Catalysis by Alcohol Dehydrogenases
    BRYCE PLAPP; Fiscal Year: 2009
    ..Design of better inhibitors for treating the pathology of alcoholism depends on understanding the dynamics of catalysis by the rate-limiting enzyme in the pathway of alcohol metabolism. ..
  29. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  30. Liver to Endocrine Pancreas Transdifferentiation
    Lijun Yang; Fiscal Year: 2009
    ..abstract_text> ..
  31. Immediate-Early Genes of KSHV
    Yan Yuan; Fiscal Year: 2009
    ..In addition, the results from the proposed studies will provide assessment of whether targeting KSHV IE proteins ORF45 could be new strategies for therapeutic intervention for KSHV-associated diseases. ..
  32. Signaling mechanisms of axon regeneration by CNS myelin
    Zhigang He; Fiscal Year: 2009
    ..The second aim will investigate the downstream signaling mechanisms mediated by p75, TROY and perhaps other functionally similar molecules. The involvement of Lingo-1 in this receptor complex will be addressed in the third aim. ..
  33. TrialNet: University of Florida Clinical Center and Network
    Desmond Schatz; Fiscal Year: 2007
    ..It is thus a promising agent to consider for the prevention of Type 1 diabetes. ..
  34. CANCER GENETICS NETWORK
    Claudine Isaacs; Fiscal Year: 2006
    ....
  35. Signaling Mechanisms mediating effects of Semaphorin3A
    Zhigang He; Fiscal Year: 2005
    ....
  36. PARP Inhibitors for Chemotherapy of Brain Tumors
    Jie Zhang; Fiscal Year: 2004
    ..abstract_text> ..
  37. PARP Inhibitors for Treating Cardiac Arrest
    Jie Zhang; Fiscal Year: 2004
    ..abstract_text> ..
  38. SPECIFICITY AND FUNCTION OF ALCOHOL DEHYDROGENASES
    BRYCE PLAPP; Fiscal Year: 2004
    ....
  39. Research Echocardiography System
    Thomas Force; Fiscal Year: 2004
    ....
  40. MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
    Jared Gollob; Fiscal Year: 2004
    ....
  41. FRA16D CHROMOSOMAL FRAGILE SITE IN LIVER CARCINOGENESIS
    Lewis Roberts; Fiscal Year: 2003
    ..This will enable me to obtain the training and preliminary data I need to launch an independent, productive research career. ..
  42. Semaphorins and Axon Regeneration in Spinal Cord Injury
    Zhigang He; Fiscal Year: 2003
    ....
  43. Biochemical Stabilization for Freeze Dried Platelets
    Christopher Wagner; Fiscal Year: 2003
    ..abstract_text> ..
  44. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Since many of the studies include analysis of pharmacological specimens, the Committee utilizes three core laboratories--at the University of Chicago, the University of Maryland and the University of Tennessee. ..
  45. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
    ..abstract_text> ..
  46. IL-4 Signaling Pathway Regulation of Sjogren's Syndrome
    AMMON PECK; Fiscal Year: 2004
    ..Identification of this effector mechanism could be important to the long-term goal of developing targeted preventive or early intervention strategies. ..
  47. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  48. NAD+ control of transcriptional silencing and longevity
    David Sinclair; Fiscal Year: 2007
    ..As far as we are aware, our approach to understanding this fundamental regulatory network is unique. [unreadable] [unreadable]..
  49. K Vitamins- A New Class of Liver Cell Growth Inhibitors
    Brian Carr; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  50. REGULATION OF ENTERIC HYPEROXALURI BY OXALOBACTER
    AMMON PECK; Fiscal Year: 2001
    ..formigenes plays in regulating oxalate homeostasis in vertebrates, including humans, and should offer new modalities in prevention therapy for oxalate-associated disorders, such as recurrent kidney stone formation. ..
  51. MOLECULAR STRUCTURE OF STEROIDS
    William Duax; Fiscal Year: 2006
    ..Proof of the successful prediction of the structures of 20-30 hypothetical members of the SCOR proteome could provide a model for the prediction of protein folding on the basis of as little as 20% sequence homology. ..
  52. Autoimmunity of hepatocyte-derived insulin-producing*
    Lijun Yang; Fiscal Year: 2005
    ..The information derived from these experiments is critical for translating the results of liver to endocrine pancreas transdifferentiation into clinical application for gene and cell based therapies aimed at curing TIDM. ..
  53. Transdifferentiation of hepatocytes
    Lijun Yang; Fiscal Year: 2005
    ..abstract_text> ..
  54. Regulation of Neuronal Nicotinic Receptors
    Lynn Wecker; Fiscal Year: 2005
    ....
  55. Evaluating Clinical Benefit in Sarcomas
    Robert Benjamin; Fiscal Year: 2004
    ..Speakers will be radiologists and medical oncologists. The intended audience is the FDA, the NCI and oncologists. The ultimate goal is to publish the proceedings of this meeting. ..
  56. Insulin producing cells generated in vitro from hepatic stem cells
    Lijun Yang; Fiscal Year: 2007
    ..abstract_text> ..
  57. Molecular Dynamics Simulation of Aldehyde Dehydrogenase
    Troy Wymore; Fiscal Year: 2002
    ..Finally, by integrating these calculation results with those from sequence analysis and site-directed mutagenesis experiments, we intend to understand the molecular factors that influence all ALDHs. ..
  58. M3 Receptor--Diagnostic Marker for Sjogren's Syndrome
    AMMON PECK; Fiscal Year: 2003
    ..Final development of a simple, non-surgical, Sjogren's syndrome-specific diagnostic test would be a welcome addition to the patient, the treating physician, and the clinical laboratory. ..
  59. Yeast screens for genetic & chemical mimetics of CR
    David Sinclair; Fiscal Year: 2006
    ..The longer-term goal is to test the genes and compounds we identify for their ability to extend life span in C. elegans. The knowledge gained should serve to guide searches for compounds that retard aging in mammals. ..
  60. Oxalobacter as a therapy in IBD-associated urolithiasis
    AMMON PECK; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  61. ZINC NEUROTOXICITY
    Christian Sheline; Fiscal Year: 2004
    ....
  62. Prevention of Neuronal Damage in Optic Neuritis
    KENNETH SHINDLER; Fiscal Year: 2008
    ..This proposal will serve as an ideal platform for the principal investigator to begin a career aimed at understanding mechanisms of optic nerve damage and its correlation to clinical findings. [unreadable] [unreadable]..